Newly released market study: Serbia Pharmaceuticals & Healthcare Report Q2 2015

A demand for austerity measures and public sector cuts by the IMF and the ongoing privatisation of state-owned enterprises will push the Serbian government to reduce its fiscal expenditure. The national health insurance fund will be pressured into reining in its costs , and we expect it will use its purchasing power to ex tr act discounts from pharmaceutical manufacturers. The outlook for the Serbian pharmaceutical market in 2015 is expected to worsen.

Headline Expenditure Projections

Pharmaceuticals: RSD92.43bn (USD1.045bn) in 2014 to RSD97.15bn (USD0.872bn) in 2015; +5.1% in local currency terms and -16.6.% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/980276_serbia_pharmaceuticals_healthcare_report_q2_2015.aspx?afid=301

Healthcare: RSD398.91bn (USD4.51bn) in 2014 to RSD423.05bn (USD3.80bn) in 2015; +6.1% in local currency terms and -15.8% in US dollar terms.

Risk/Reward Index (RRI)

Serbia's Pharmaceutical RRI score for Q215 is 50.1 out of 100, making it the 11th most attractive pharmaceutical market in Central and Eastern Europe. This is an improvement from Q115, where it was ranked 14th with a score of 48.9. The country's overall score remains below the regional average of 51.1.

Key Trends & Developments

* In March 2015, Actavis was set to launch 25 new drugs in Serbia for treating cardiovascular diseases, female healthcare, neurological disorders and psychiatric medicines.
* In March 2015, 12 drugs on the Health Insurance Fund (RFZO) reimbursement list had their co-payments reduced significantly such that patients will only need to pay the registration fee.
* In January 2015, the RFZO announced that patients would have to pay full price for more than 120 drugs, which were previously fully reimbursed or partially reimbursed. The drugs that have experienced a switch in reimbursement category include antibiotics, sedatives, statins, anti-hypertensives and other more serious diseases. The move is aimed at cooling consumption of certain, high demand medicines.

BMI Economic View: A series of planned austerity measures will weigh on domestic...

The Serbia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Serbia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Serbia pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Serbia, to test other views - a key input for successful budgeting and strategic business planning in the Serbian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- United Arab Emirates Pharmaceuticals & Healthcare Report Q2 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q2 2015
- South Korea Pharmaceuticals & Healthcare Report Q2 2015
- Italy Pharmaceuticals & Healthcare Report Q2 2015
- Peru Pharmaceuticals & Healthcare Report Q2 2015